These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 20712575)

  • 21. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.
    Marabondo S; Kaufman HL
    Expert Opin Drug Saf; 2017 Dec; 16(12):1347-1357. PubMed ID: 28929820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential IL2 Substitute Shrinks Solid Tumors.
    Cancer Discov; 2022 Aug; 12(8):1830. PubMed ID: 35758935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Regional immunotherapy of metastatic renal cell carcinoma].
    Heinzer H; Huland E; Huland H
    Urologe A; 2002 May; 41(3):239-48. PubMed ID: 12132273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.
    Dutcher JP
    Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):4-10. PubMed ID: 12469934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.
    Hashmi MH; Van Veldhuizen PJ
    Expert Opin Biol Ther; 2010 May; 10(5):807-17. PubMed ID: 20384523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of interleukin-2 in advanced renal carcinoma: meta-analysis and review of the literature.
    Malaguarnera M; Ferlito L; Gulizia G; Di Fazio I; Pistone G
    Eur J Clin Pharmacol; 2001 Jul; 57(4):267-73. PubMed ID: 11549203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Vieweg J
    Nat Clin Pract Oncol; 2005 Apr; 2(4):192-3. PubMed ID: 16264932
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
    J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New treatment approaches for metastatic renal cell carcinoma.
    Nanus DM
    Curr Oncol Rep; 2000 Sep; 2(5):417-22. PubMed ID: 11122873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pathways for managing patients receiving interleukin 2.
    Mavroukakis SA; Muehlbauer PM; White RL; Schwartzentruber DJ
    Clin J Oncol Nurs; 2001; 5(5):207-17. PubMed ID: 11905416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving the therapeutic index of IL-2.
    McDermott DF
    Clin Adv Hematol Oncol; 2010 Dec; 8(12):862-4. PubMed ID: 21326162
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.
    Clark JM; Kelley B; Titze J; Fung H; Maciejewski J; Nathan S; Rich E; Basu S; Kaufman HL
    Oncology; 2013; 84(2):123-6. PubMed ID: 23235386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
    McDermott DF; Regan MM; Atkins MB
    Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
    Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
    Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials.
    Atkins MB; Dutcher J; Weiss G; Margolin K; Clark J; Sosman J; Logan T; Aronson F; Mier J;
    Med Oncol; 2001; 18(3):197-207. PubMed ID: 11917944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
    Hutson TE; Quinn DI
    Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained ventricular tachycardia and its successful prophylaxis during high-dose bolus interleukin-2 therapy for metastatic renal cell carcinoma.
    Oleksowicz L; Escott P; Leichman GC; Spangenthal E
    Am J Clin Oncol; 2000 Feb; 23(1):34-6. PubMed ID: 10683072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cytokine therapy for metastatic renal cell carcinoma].
    Eto M; Naito S
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2.
    Engelhardt M; Wirth K; Mertelsmann R; Lindemann A; Brennscheidt U
    Eur J Cancer; 1997 Jun; 33(7):1050-4. PubMed ID: 9376186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokine therapy for metastatic renal cell carcinoma.
    Bukowski RM
    Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.